Leptin in congenital or HIV-associated lipodystrophy and metabolic syndrome: A need for more mechanistic studies and large, randomized, placebo-controlled trials

Metabolism: Clinical and Experimental

Volumn 61, Issue 10, 2012, Pages 1331-1336

  Foo, Joo Pin ^a   Mantzoros, Christos S ^a,b  

^a HARVARD MEDICAL SCHOOL   (United States)

^b Medical School   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADIPONECTIN; ALPHA INTERFERON; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; METRELEPTIN; PIOGLITAZONE; PLACEBO; PROTEINASE INHIBITOR; RECOMBINANT LEPTIN; RNA DIRECTED DNA POLYMERASE INHIBITOR; TRIACYLGLYCEROL; TUMOR NECROSIS FACTOR;

CARDIOVASCULAR RISK; CELL DIFFERENTIATION; CONGENITAL GENERALIZED LIPODYSTROPHY; DISEASE MARKER; DRUG EFFECT; DYSLIPIDEMIA; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HIV ASSOCIATED LIPODYSTROPHY; HUMAN; INSULIN RESISTANCE; INSULIN SENSITIVITY; LIPID METABOLISM; LIPID STORAGE; LIPOPROTEIN METABOLISM; METABOLIC SYNDROME X; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; REVIEW;

EID: 84866732105     PISSN: 00260495     EISSN: 15328600     Source Type: Journal    
DOI: 10.1016/j.metabol.2012.04.013     Document Type: Editorial

References (65)

1. A. Garg Acquired and inherited lipodystrophies N Engl J Med 350 12 2004 1220 1234 (Pubitemid 38339366)
2. A. Mocroft Decline in the AIDS and death rates in the EuroSIDA study: an observational study Lancet 362 9377 2003 22 29 (Pubitemid 36835816)
3. R. Power A qualitative study of the psychosocial implications of lipodystrophy syndrome on HIV positive individuals Sex Transm Infect 79 2 2003 137 141 (Pubitemid 36469620)
4. C. Grunfeld Lipids, lipoproteins, triglyceride clearance, and cytokines in human immunodeficiency virus infection and the acquired immunodeficiency syndrome J Clin Endocrinol Metab 74 5 1992 1045 1052
5. K.R. Feingold The hypertriglyceridemia of acquired immunodeficiency syndrome is associated with an increased prevalence of low density lipoprotein subclass pattern B J Clin Endocrinol Metab 76 6 1993 1423 1427 (Pubitemid 23164355)
6. F. Magkos, and C.S. Mantzoros Body fat redistribution and metabolic abnormalities in HIV-infected patients on highly active antiretroviral therapy: novel insights into pathophysiology and emerging opportunities for treatment Metabolism 60 6 2011 749 753
7. A. Carr Diagnosis, prediction, and natural course of HIV-1 protease-inhibitor-associated lipodystrophy, hyperlipidaemia, and diabetes mellitus: a cohort study Lancet 353 9170 1999 2093 2099 (Pubitemid 29278477)
8. J.C. Shlay Long-term body composition and metabolic changes in antiretroviral naive persons randomized to protease inhibitor-, nonnucleoside reverse transcriptase inhibitor-, or protease inhibitor plus nonnucleoside reverse transcriptase inhibitor-based strategy J Acquir Immune Defic Syndr 44 5 2007 506 517 (Pubitemid 46594893)
9. P. Bonfanti HIV and metabolic syndrome: a comparison with the general population J Acquir Immune Defic Syndr 45 4 2007 426 431 (Pubitemid 47057669)
10. D. Dimock Longitudinal assessment of metabolic abnormalities in adolescents and young adults with HIV-infection acquired perinatally or in early childhood Metabolism 60 6 2011 874 880
11. J.H. Stein Use of human immunodeficiency virus-1 protease inhibitors is associated with atherogenic lipoprotein changes and endothelial dysfunction Circulation 104 3 2001 257 262 (Pubitemid 32666944)
12. N. Friis-Moller Combination antiretroviral therapy and the risk of myocardial infarction N Engl J Med 349 21 2003 1993 2003
13. M.K. Leow, C.L. Addy, and C.S. Mantzoros Clinical review 159: human immunodeficiency virus/highly active antiretroviral therapy-associated metabolic syndrome: clinical presentation, pathophysiology, and therapeutic strategies J Clin Endocrinol Metab 88 55 2003 1961 1976 (Pubitemid 36549862)
14. D.E. Sellmeyer, and C. Grunfeld Endocrine and metabolic disturbances in human immunodeficiency virus infection and the acquired immune deficiency syndrome Endocr Rev 17 5 1996 518 532 (Pubitemid 26346641)
15. L. Calza, R. Manfredi, and F. Chiodo Hyperlipidaemia in patients with HIV-1 infection receiving highly active antiretroviral therapy: epidemiology, pathogenesis, clinical course and management Int J Antimicrob Agents 22 2 2003 89 99 (Pubitemid 36970166)
16. C. Grunfeld Circulating interferon-alpha levels and hypertriglyceridemia in the acquired immunodeficiency syndrome Am J Med 90 2 1991 154 162
17. A. Carr Pathogenesis of HIV-1-protease inhibitor-associated peripheral lipodystrophy, hyperlipidaemia, and insulin resistance Lancet 351 1998 1881 1883 (Pubitemid 28279721)
18. T.N. Kakuda, K.A. Struble, and S.C. Piscitelli Protease inhibitors for the treatment of human immunodeficiency virus infection Am J Health Syst Pharm 55 3 1998 233 254 (Pubitemid 28109897)
19. P. Tontonoz, E. Hu, and B.M. Spiegelman Regulation of adipocyte gene expression and differentiation by peroxisome proliferator activated receptor gamma Curr Opin Genet Dev 5 5 1995 571 576
20. S.R. Penzak, and S.K. Chuck Hyperlipidemia associated with HIV protease inhibitor use: pathophysiology, prevalence, risk factors and treatment Scand J Infect Dis 32 2 2000 111 123 (Pubitemid 30599192)
21. C.S. Mantzoros The role of leptin in human obesity and disease: a review of current evidence Ann Intern Med 130 8 1999 671 680 (Pubitemid 29196202)
22. C. Weyer Hypoadiponectinemia in obesity and type 2 diabetes: close association with insulin resistance and hyperinsulinemia J Clin Endocrinol Metab 86 5 2001 1930 1935 (Pubitemid 32472900)
23. G.S. Nagy Human immunodeficiency virus type 1-related lipoatrophy and lipohypertrophy are associated with serum concentrations of leptin Clin Infect Dis 36 6 2003 795 802 (Pubitemid 36337987)
24. C.L. Addy Hypoadiponectinemia is associated with insulin resistance, hypertriglyceridemia, and fat redistribution in human immunodeficiency virus-infected patients treated with highly active antiretroviral therapy J Clin Endocrinol Metab 88 2 2003 627 636 (Pubitemid 36207802)
25. P. Pisto Plasma adiponectin - an independent indicator of liver fat accumulation Metabolism 60 11 2011 1515 1520
26. K. Tsuzaki The relationship between adiponectin, an adiponectin gene polymorphism, and high-density lipoprotein particle size: from the Mima study Metabolism 61 1 2012 17 21
27. S.A. Polyzos Serum total adiponectin in nonalcoholic fatty liver disease: a systematic review and meta-analysis Metabolism 60 3 2011 313 326
28. L.H. Duntas, V. Popovic, and G. Panotopoulos Adiponectin: novelties in metabolism and hormonal regulation Nutr Neurosci 7 4 2004 195 200 (Pubitemid 40123571)
29. A. Xu Adiponectin ameliorates dyslipidemia induced by the human immunodeficiency virus protease inhibitor ritonavir in mice Endocrinology 145 2 2004 487 494 (Pubitemid 38183790)
30. I. Shimomura Leptin reverses insulin resistance and diabetes mellitus in mice with congenital lipodystrophy Nature 401 6748 1999 73 76
31. E. Asilmaz Site and mechanism of leptin action in a rodent form of congenital lipodystrophy J Clin Invest 113 3 2004 414 424 (Pubitemid 38544185)
32. K. Ebihara Transgenic overexpression of leptin rescues insulin resistance and diabetes in a mouse model of lipoatrophic diabetes Diabetes 50 6 2001 1440 1448 (Pubitemid 32500178)
33. W.T. Donahoo Leptin increases skeletal muscle lipoprotein lipase and postprandial lipid metabolism in mice Metabolism 60 3 2011 438 443
34. T. Yamauchi The fat-derived hormone adiponectin reverses insulin resistance associated with both lipoatrophy and obesity Nat Med 7 5 2001 941 946 (Pubitemid 32756432)
35. Y.H. Lee Effects of leptin and adiponectin on pancreatic beta-cell function Metabolism 60 12 2011 1664 1672
36. R.V. Sekhar Effects of rosiglitazone on abnormal lipid kinetics in HIV-associated dyslipidemic lipodystrophy: a stable isotope study Metabolism 60 6 2011 754 760
37. E. Arioglu Efficacy and safety of troglitazone in the treatment of lipodystrophy syndromes Ann Intern Med 133 4 2000 263 274 (Pubitemid 30660298)
38. A. Carr No effect of rosiglitazone for treatment of HIV-1 lipoatrophy: randomised, double-blind, placebo-controlled trial Lancet 363 9407 2004 429 438 (Pubitemid 38210059)
39. J. Sutinen Rosiglitazone in the treatment of HAART-associated lipodystrophy-a randomized double-blind placebo-controlled study Antivir Ther 8 3 2003 199 207 (Pubitemid 36960893)
40. R.B. Cavalcanti A randomized, placebo-controlled trial of rosiglitazone for HIV-related lipoatrophy J Infect Dis 195 12 2007 1754 1761 (Pubitemid 46870247)
41. C. Hadigan Metabolic effects of rosiglitazone in HIV lipodystrophy: a randomized, controlled trial Ann Intern Med 140 10 2004 786 794
42. A. Gavrila Improvement in highly active antiretroviral therapy-induced metabolic syndrome by treatment with pioglitazone but not with fenofibrate: a 2 × 2 factorial, randomized, double-blinded, placebo-controlled trial Clin Infect Dis 40 5 2005 745 749 (Pubitemid 40381352)
43. C.S. Mantzoros Leptin in human physiology and pathophysiology Am J Physiol Endocrinol Metab 301 4 2011 E567 E584
44. E.A. Oral Leptin-replacement therapy for lipodystrophy N Engl J Med 346 8 2002 570 578 (Pubitemid 34438818)
45. K.F. Petersen Leptin reverses insulin resistance and hepatic steatosis in patients with severe lipodystrophy J Clin Invest 109 10 2002 1345 1350 (Pubitemid 34546899)
46. K. Ebihara, H. Masuzaki, and K. Nakao Long-term leptin-replacement therapy for lipoatrophic diabetes N Engl J Med 351 6 2004 615 616 (Pubitemid 39025183)
47. E.D. Javor Leptin reverses nonalcoholic steatohepatitis in patients with severe lipodystrophy Hepatology 41 4 2005 753 760 (Pubitemid 40462937)
48. J.H. Lee Recombinant methionyl human leptin therapy in replacement doses improves insulin resistance and metabolic profile in patients with lipoatrophy and metabolic syndrome induced by the highly active antiretroviral therapy J Clin Endocrinol Metab 91 7 2006 2605 2611 (Pubitemid 44024625)
49. K. Mulligan The effects of recombinant human leptin on visceral fat, dyslipidemia, and insulin resistance in patients with human immunodeficiency virus-associated lipoatrophy and hypoleptinemia J Clin Endocrinol Metab 94 4 2009 1137 1144
50. C.S. Mantzoros Whither recombinant human leptin treatment for HIV-associated lipoatrophy and the metabolic syndrome? J Clin Endocrinol Metab 94 4 2009 1089 1091
51. F. Magkos Leptin replacement improves postprandial glycemia and insulin sensitivity in human immunodeficiency virus-infected lipoatrophic men treated with pioglitazone: a pilot study Metabolism 60 7 2011 1045 1049
52. R.V. Sekhar, F. Jahoor, D. Iyer, A. Guthikonda, J. Paranilam, F. Elhaj, I. Coraza, and A. Balasubramanyam Leptin replacement therapy does not improve the abnormal lipid kinetics of hypoleptinemic patients with HIV-associated lipodystrophy syndrome Metabolism 2012 In Press
53. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S) Lancet 344 8934 1994 1383 1389
54. C.J. Fichtenbaum, and J.G. Gerber Interactions between antiretroviral drugs and drugs used for the therapy of the metabolic complications encountered during HIV infection Clin Pharmacokinet 41 14 2002 1195 1211 (Pubitemid 35398692)
55. S. Tsiodras, and C.S. Mantzoros Drug-drug interactions in HIV medicine: a not so simple and straightforward road to the future Metabolism 60 11 2011 1497 1499
56. Y. Daali Ritonavir inhibits the two main prasugrel bioactivation pathways in vitro: a potential drug-drug interaction in HIV patients Metabolism 60 11 2011 1584 1589
57. A.P. Rahman Safety and efficacy of simvastatin for the treatment of dyslipidemia in human immunodeficiency virus-infected patients receiving efavirenz-based highly active antiretroviral therapy Pharmacotherapy 28 6 2008 913 919 (Pubitemid 351875170)
58. A. Rao Fenofibrate is effective in treating hypertriglyceridemia associated with HIV lipodystrophy Am J Med Sci 327 6 2004 315 318 (Pubitemid 38780174)
59. Ginsberg, H.N., Hypertriglyceridemia: new insights and new approaches to pharmacologic therapy. The American journal of cardiology, 2001. 87(10): p. 1174 - 80; A4. (Pubitemid 32453238)
60. J. Falutz Metabolic effects of a growth hormone-releasing factor in patients with HIV N Engl J Med 357 23 2007 2359 2370 (Pubitemid 350223390)
61. J. Falutz Effects of tesamorelin (TH9507), a growth hormone-releasing factor analog, in human immunodeficiency virus-infected patients with excess abdominal fat: a pooled analysis of two multicenter, double-blind placebo-controlled phase 3 trials with safety extension data J Clin Endocrinol Metab 95 9 2010 4291 4304
62. S.W. Worm Risk of myocardial infarction in patients with HIV infection exposed to specific individual antiretroviral drugs from the 3 major drug classes: the data collection on adverse events of anti-HIV drugs (D:A:D) study J Infect Dis 201 3 2010 318 330
63. V.A. Triant, J.B. Meigs, and S.K. Grinspoon Association of C-reactive protein and HIV infection with acute myocardial infarction J Acquir Immune Defic Syndr 51 3 2009 268 273
64. V.A. Triant Association of immunologic and virologic factors with myocardial infarction rates in a US healthcare system J Acquir Immune Defic Syndr 55 5 2010 615 619
65. D. Costagliola Abacavir and cardiovascular risk: reviewing the evidence Curr HIV/AIDS Rep 7 2010 127 133